MedPath

PYLERA

These highlights do not include all the information needed to use PYLERA safely and effectively. See full prescribing information for PYLERA PYLERA (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) capsules, for oral use Initial U.S. Approval: 2006

Approved
Approval ID

5cdacbf5-67be-42eb-bd54-8acc32ea1abc

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 19, 2023

Manufacturers
FDA

H2-Pharma, LLC

DUNS: 028473634

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, and TETRACYCLINE HYDROCHLORIDE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code61269-380
Application NumberNDA050786
Product Classification
M
Marketing Category
C73594
G
Generic Name
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, and TETRACYCLINE HYDROCHLORIDE
Product Specifications
Route of AdministrationORAL
Effective DateOctober 19, 2023
FDA Product Classification

INGREDIENTS (8)

BISMUTH SUBCITRATE POTASSIUMActive
Quantity: 140 mg in 1 1
Code: R3O80H60KX
Classification: ACTIB
METRONIDAZOLEActive
Quantity: 125 mg in 1 1
Code: 140QMO216E
Classification: ACTIB
TETRACYCLINE HYDROCHLORIDEActive
Quantity: 125 mg in 1 1
Code: P6R62377KV
Classification: ACTIB
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327L
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

PYLERA - FDA Drug Approval Details